Top Tweets for #NIFTYSML

Alembic Pharma Secures USFDA Approval for Prucalopride Tablets 📈 | MCap 16,151.59 Cr - Alembic Pharmaceuticals received USFDA final approval for Prucalopride Tablets (1 mg & 2 mg). - The product is therapeutically equivalent to Takeda's Motegrity Tablets. - It is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. - The estimated market size for Prucalopride Tablets is US$ 100 million for the twelve months ending March 2026 (IQVIA data). - This brings Alembic's cumulative USFDA ANDA approvals to 245 (225 final, 20 tentative). Disc: Information provided in above tweet can be inaccurate, verify through the source i.e. attached image(s) & in reply before making any investment decision.